2-(3’-吡啶基l)苯乙酸 | 675602-63-8

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-(3’-吡啶基l)苯乙酸
• 中文别名: 2-(3-吡啶)苯乙酸；2-(3'-吡啶基)苯乙酸；2-(3'-吡啶基L)苯乙酸
• 英文名称: 2-[2-(pyridin-3-yl)phenyl]acetic acid
• 英文别名: (2-pyridin-3-ylphenyl)acetic acid；2-(3'-Pyridyl)phenylacetic acid；2-(2-pyridin-3-ylphenyl)acetic acid
• CAS: 675602-63-8
• 化学式: C₁₃H₁₁NO₂
• mdl: MFCD03426516
• 分子量: 213.236
• InChiKey: PMPVQDCSSJCWGH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  2-(3’-吡啶基l)苯乙酸 在 氯化亚砜 、 氨 作用下， 反应 1.0h， 生成 2-[2-(pyridin-3-yl)phenyl]acetamide
  参考文献：
  名称：

  Substituted 2-[2-(pyridin-3-yl) phenyl] acetamides and ureas: design, synthesis, and anticonvulsant screening in mice

  摘要：

  Five novel 2-[2[(pyridin-3-yl) phenyl] acetamides and ureas were designed based on a two-point pharmacophore, synthesized by improved methods, and screened for anticonvulsant activity in maximal electroshock seizure (MES) and ScPTZ-induced seizure models in Swiss mice at doses of 30, 100, and 300 mg/kg body weight. Compound 15 displayed potent anticonvulsant activity in MES test with ED50 value of 8.28 mg/kg and higher protective index (TD50/ED50 = 26) compared with Phenytoin, which can be considered as a promising lead.

  DOI：

  10.1007/s00044-011-9717-y

文献信息

• Novel Specific Caspase-10 Inhibitors
  申请人：Lardy Claude

  公开号：US20080255173A1

  公开（公告）日：2008-10-16

  The invention relates to compounds of the general formula (I), and to their use as caspase-10 inhibitors, especially for the treatment of diabetic retinopathy.

  本发明涉及通式(I)的化合物及其作为caspase-10抑制剂的用途，尤其是用于治疗糖尿病视网膜病变。
• Substituted Piperazines as CB1 Antagonists
  申请人：Gilbert Eric J.

  公开号：US20100029607A1

  公开（公告）日：2010-02-04

  Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB 1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.

  式(I)的化合物，或其药学上可接受的盐、溶剂合物或酯类，可用于治疗由CB1受体介导的疾病或症状，例如代谢综合征和肥胖症、神经炎性疾病、认知障碍和精神病、成瘾（例如戒烟）、胃肠疾病和心血管病症。
• PHARMACEUTICAL COMPOSITION AND METHOD
  申请人：Slade Rachel M.

  公开号：US20090155903A1

  公开（公告）日：2009-06-18

  The invention provides compounds, pharmaceutical compositions and methods for the therapeutic treatment and prevention of neurodegenerative disorder and other Aβ 42 -related diseases and disorders.

  该发明提供了化合物、制药组合物和方法，用于治疗和预防神经退行性疾病和其他与Aβ42相关的疾病和障碍。
• Fused benzeneoxyacetic acid derivatives
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP0548949B1

  公开（公告）日：1997-09-17
• NOVEL SPECIFIC CASPASE-10 INHIBITORS
  申请人：Merck Patent GmbH

  公开号：EP1817031A1

  公开（公告）日：2007-08-15